Protective effect of carvacrol on liver injury in type 2 diabetic db/db mice

Zhao,Wei; Chen,Li; Zhou,Heng; Deng,Chunyan; Han,Qizhen; Chen,Yonghua; Wu,Qing; Li,Shanshan

doi:10.3892/mmr.2021.12381

Protective effect of carvacrol on liver injury in type 2 diabetic db/db mice

Authors:
- Wei Zhao
- Li Chen
- Heng Zhou
- Chunyan Deng
- Qizhen Han
- Yonghua Chen
- Qing Wu
- Shanshan Li
View Affiliations

Affiliations: Department of Endocrinology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550003, P.R. China, Department of Prevention and Health Care, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550003, P.R. China, Department of Endocrinology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550003, P.R. China
Published online on: August 24, 2021 https://doi.org/10.3892/mmr.2021.12381
Article Number: 741
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the protective effect of carvacrol on liver injury in mice with type 2 diabetes mellitus (T2DM) and to assess its potential molecular mechanism. Mice were divided into three groups (n=15/group): Non‑diabetic db/m+ mice group, db/db mice group and db/db mice + carvacrol group. In the db/db mice + carvacrol group, db/db mice were administered 10 mg/kg carvacrol daily by gavage for 6 weeks. Fasting blood glucose and insulin levels were separately examined. Pathological changes were observed using hematoxylin and eosin, Masson's trichrome, periodic acid Schiff and reticular fiber staining. In addition, immunohistochemistry, immunofluorescence and western blotting were used to examine the expression levels of Toll‑like receptor 4 (TLR4), NF‑κB, NALP3, AKT1, phosphorylated (p)‑AKT1, insulin receptor (INSR), p‑INSR, mTOR, p‑mTOR, insulin receptor substrate 1 (IRS1) and p‑IRS1 in the liver tissues. The results revealed that carvacrol improved blood glucose and insulin resistance of T2DM db/db mice. After treatment with carvacrol for 6 weeks, the serum levels of TC, TG and LDL‑C were markedly reduced, whereas HDL‑C levels were significantly increased in db/db mice. Furthermore, carvacrol administration significantly decreased serum ALT and AST levels in db/db mice. Serum BUN, Cre and UA levels were markedly higher in db/db mice compared with those in the control group; however, carvacrol treatment markedly reduced their serum levels in db/db mice. Furthermore, histological examinations confirmed that carvacrol could protect the liver of db/db mice. Carvacrol could ameliorate liver injury induced by T2DM via mediating insulin, TLR4/NF‑κB and AKT1/mTOR signaling pathways. The present findings suggested that carvacrol exerted protective effects on the liver in T2DM db/db mice, which could be related to insulin, TLR4/NF‑κB and AKT1/mTOR signaling pathways.

View Figures

View References

1	Liang W, Zhang D, Kang J, Meng X, Yang J, Yang L, Xue N, Gao Q, Han S and Gou X: Protective effects of rutin on liver injury in type 2 diabetic db/db mice. Biomed Pharmacother. 107:721–728. 2018. View Article : Google Scholar : PubMed/NCBI
2	Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U and Shaw JE: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 103:137–149. 2014. View Article : Google Scholar : PubMed/NCBI
3	Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J and Vos MB: Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 69:2672–2682. 2019. View Article : Google Scholar : PubMed/NCBI
4	Yang H, Yang T, Heng C, Zhou Y, Jiang Z, Qian X, Du L, Mao S, Yin X and Lu Q: Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice. Phytother Res. 33:3140–3152. 2019. View Article : Google Scholar : PubMed/NCBI
5	Chang TC, Chiang H, Lai YH, Huang YL, Huang HC, Liang YC, Liu HK and Huang C: Helminthostachys zeylanica alleviates hepatic steatosis and insulin resistance in diet-induced obese mice. BMC Complement Altern Med. 19:3682019. View Article : Google Scholar : PubMed/NCBI
6	Leung PS: The Modulatory action of Vitamin D on the Renin-Angiotensin System and the determination of hepatic insulin resistance. Molecules. 24:24792019. View Article : Google Scholar : PubMed/NCBI
7	Wang CC, Cheng PN and Kao JH: Systematic review: Chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 51:216–230. 2020. View Article : Google Scholar : PubMed/NCBI
8	Li DJ, Liu J, Hua X, Fu H, Huang F, Fei YB, Lu WJ, Shen FM and Wang P: Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease. Metabolism. 79:52–63. 2018. View Article : Google Scholar : PubMed/NCBI
9	Liu C, Liao JZ and Li PY: Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease. World J Gastroenterol. 23:1964–1973. 2017. View Article : Google Scholar : PubMed/NCBI
10	Scheen AJ: Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 45:213–223. 2019. View Article : Google Scholar : PubMed/NCBI
11	Guan X, Li X, Yang X, Yan J, Shi P, Ba L, Cao Y and Wang P: The neuroprotective effects of carvacrol on ischemia/reperfusion-induced hippocampal neuronal impairment by ferroptosis mitigation. Life Sci. 235:1167952019. View Article : Google Scholar : PubMed/NCBI
12	Zhao W, Deng C, Han Q, Xu H and Chen Y: Carvacrol may alleviate vascular inflammation in diabetic db/db mice. Int J Mol Med. 46:977–988. 2020. View Article : Google Scholar : PubMed/NCBI
13	de Carvalho FO, Silva ÉR, Gomes IA, Santana HS, do Nascimento Santos D, de Oliveira Souza GP, de Jesus Silva D, Monteiro JC, de Albuquerque Júnior RLC, de Souza Araújo AA and Nunes PS: Anti-inflammatory and antioxidant activity of carvacrol in the respiratory system: A systematic review and meta-analysis. Phytother Res. 34:2214–2229. 2020. View Article : Google Scholar : PubMed/NCBI
14	Cardoso AD, Santos EG, Lima AD, Temeyer KB, Pérez de León AA, Costa LM Junior and Soares AM: Terpenes on Rhipicephalus (Boophilus) microplus: Acaricidal activity and acetylcholinesterase inhibition. Vet Parasitol. 280:1090902020. View Article : Google Scholar : PubMed/NCBI
15	Trindade GG, Thrivikraman G, Menezes PP, França CM, Lima BS, Carvalho YM, Souza EP, Duarte MC, Shanmugam S, Quintans-Júnior LJ, et al: Carvacrol/β-cyclodextrin inclusion complex inhibits cell proliferation and migration of prostate cancer cells. Food Chem Toxicol. 125:198–209. 2019. View Article : Google Scholar : PubMed/NCBI
16	Liu Y, Wei J, Ma KT, Li CL, Mai YP, Qiu XX, Wei H, Hou N and Luo JD: Carvacrol protects against diabetes-induced hypercontractility in the aorta through activation of the PI3K/Akt pathway. Biomed Pharmacother. 125:1098252020. View Article : Google Scholar : PubMed/NCBI
17	Hou N, Mai Y, Qiu X, Yuan W, Li Y, Luo C, Liu Y, Zhang G, Zhao G and Luo JD: Carvacrol attenuates diabetic cardiomyopathy by modulating the PI3K/AKT/GLUT4 Pathway in diabetic mice. Front Pharmacol. 10:9982019. View Article : Google Scholar : PubMed/NCBI
18	Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K and Chan L: The db/db mouse, a model for diabetic dyslipidemia: Molecular characterization and effects of Western diet feeding. Metabolism. 49:22–31. 2000. View Article : Google Scholar : PubMed/NCBI
19	Peng BY, Wang Q, Luo YH, He JF, Tan T and Zhu H: A novel and quick PCR-based method to genotype mice with a leptin receptor mutation (db/db mice). Acta Pharmacol Sin. 39:117–123. 2018. View Article : Google Scholar : PubMed/NCBI
20	National Research Council Committee for the Update of the Guide for the C, Use of Laboratory A. The National Academies Collection, . Reports funded by National Institutes of Health. Guide for the Care and Use of Laboratory Animals. National Academies Press; Washington, DC: 2011, PubMed/NCBI
21	Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y and Morii H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 22:818–822. 1999. View Article : Google Scholar : PubMed/NCBI
22	Prasanna PL, Renu K and Valsala Gopalakrishnan A: New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sci. 250:1175992020. View Article : Google Scholar : PubMed/NCBI
23	Sampath Kumar A, Maiya AG, Shastry BA, Vaishali K, Ravishankar N, Hazari A, Gundmi S and Jadhav R: Exercise and insulin resistance in type 2 diabetes mellitus: A systematic review and meta-analysis. Ann Phys Rehabil Med. 62:98–103. 2019. View Article : Google Scholar : PubMed/NCBI
24	Zheng Y, Liu T, Wang Z, Xu Y, Zhang Q and Luo D: Low molecular weight fucoidan attenuates liver injury via SIRT1/AMPK/PGC1α axis in db/db mice. Int J Biol Macromol. 112:929–936. 2018. View Article : Google Scholar : PubMed/NCBI
25	Kim KE, Jung Y, Min S, Nam M, Heo RW, Jeon BT, Song DH, Yi CO, Jeong EA, Kim H, et al: Caloric restriction of db/db mice reverts hepatic steatosis and body weight with divergent hepatic metabolism. Sci Rep. 6:301112016. View Article : Google Scholar : PubMed/NCBI
26	Eckel RH, Grundy SM and Zimmet PZ: The metabolic syndrome. Lancet. 365:1415–1428. 2005. View Article : Google Scholar : PubMed/NCBI
27	Meng Q, Qi X, Fu Y, Chen Q, Cheng P, Yu X, Sun X, Wu J, Li W, Zhang Q, et al: Flavonoids extracted from mulberry (Morus alba L.) leaf improve skeletal muscle mitochondrial function by activating AMPK in type 2 diabetes. J Ethnopharmacol. 248:1123262020. View Article : Google Scholar : PubMed/NCBI
28	Berk PD and Verna EC: Nonalcoholic fatty liver disease: Lipids and insulin resistance. Clin Liver Dis. 20:245–262. 2016. View Article : Google Scholar : PubMed/NCBI
29	Sattar N, Fitchett D, Hantel S, George JT and Zinman B: Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: Results from randomised trials including the EMPA-REG OUTCOME^® trial. Diabetologia. 61:2155–2163. 2018. View Article : Google Scholar : PubMed/NCBI
30	Liu HW, Kao HH and Wu CH: Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice. Nutr Metab (Lond). 16:222019. View Article : Google Scholar : PubMed/NCBI
31	Cobbina E and Akhlaghi F: Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 49:197–211. 2017. View Article : Google Scholar : PubMed/NCBI
32	Mohseni R, Karimi J, Tavilani H, Khodadadi I and Hashemnia M: Carvacrol ameliorates the progression of liver fibrosis through targeting of Hippo and TGF-β signaling pathways in carbon tetrachloride (CCl₄)-induced liver fibrosis in rats. Immunopharmacol Immunotoxicol. 41:163–171. 2019. View Article : Google Scholar : PubMed/NCBI
33	Ozen BD and Uyanoglu M: Effect of carvacrol on IL-6/STAT3 pathway after partial hepatectomy in rat liver. Bratisl Lek Listy. 119:593–601. 2018.PubMed/NCBI
34	Ding S, Xu S, Ma Y, Liu G, Jang H and Fang J: Modulatory mechanisms of the NLRP3 inflammasomes in diabetes. Biomolecules. 9:8502019. View Article : Google Scholar : PubMed/NCBI
35	Yin H, Huang L, Ouyang T and Chen L: Baicalein improves liver inflammation in diabetic db/db mice by regulating HMGB1/TLR4/NF-κB signaling pathway. Int Immunopharmacol. 55:55–62. 2018. View Article : Google Scholar : PubMed/NCBI
36	Liu ZM, Zheng HY, Chen LH, Li YL, Wang Q, Liao CF and Li XW: Low expression of miR-203 promoted diabetic nephropathy via increasing TLR4. Eur Rev Med Pharmacol Sci. 22:5627–5634. 2018.PubMed/NCBI
37	Yi H, Peng R, Zhang LY, Sun Y, Peng HM, Liu HD, Yu LJ, Li AL, Zhang YJ, Jiang WH and Zhang Z: LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy. Cell Death Dis. 8:e25832017. View Article : Google Scholar : PubMed/NCBI
38	Pomytkin I, Krasil'nikova I, Bakaeva Z, Surin A and Pinelis V: Excitotoxic glutamate causes neuronal insulin resistance by inhibiting insulin receptor/Akt/mTOR pathway. Mol Brain. 12:1122019. View Article : Google Scholar : PubMed/NCBI
39	Villalobos-Labra R, Silva L, Subiabre M, Araos J, Salsoso R, Fuenzalida B, Sáez T, Toledo F, González M, Quezada C, et al: Akt/mTOR role in human foetoplacental vascular insulin resistance in diseases of pregnancy. J Diabetes Res. 2017:59478592017. View Article : Google Scholar : PubMed/NCBI